The effects of Shenkang suppository on kidney function and gut microbiota in nondialysis patients with chronic kidney disease stages 3–4: A randomized controlled trial
Frontiers in Pharmacology · 29.07.2025 · 16
DOI: 10.3389/fphar.2025.1621208 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Frontiers in Pharmacology, online erschienen am 29.07.2025. Verfasst von Weiwei Zhang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Affiliated Hospital of Xuzhou Medical University, Xuzhou, China. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Jiangsu Province.
Abstract (Originalsprache)
Background
Chronic kidney disease (CKD) patients have high prevalence and mortality rates; however, current treatment options remain limited. The Shenkang suppository (SKS) is a traditional Chinese medicine used in the clinical management of CKD. Increasing evidence suggests a close relationship between the gut microbiome and CKD. We aimed to investigate the impact of SKS on kidney function and the gut microbiota in CKD stage 3–4 patients.
Methods
It’s a single-center randomized controlled trial (n = 80). CKD stage 3–4 patients were randomly assigned at a 1:1 ratio to either the control group (n = 40) or the SKS group (n = 40) and followed for 8 weeks. Baseline data, clinical indicators, kidney markers, and stool samples were obtained from participants before and after treatment. The bacterial DNA was isolated from fecal samples and analyzed via high-throughput 16S rRNA sequencing.
Results
A total of 34 patients in the SKS group and 36 in the control group completed the study. Kidney function in the control group significantly worsened after 8 weeks ( P < 0.05 ), whereas SKS had a positive effect on slowing the progression of kidney function decline. After 8 weeks of SKS intervention, the beneficial bacteria Coriobacteriaceae and Ruminococcaceae- Ruminococcus proliferated dramatically, whereas the abundance of the harmful bacteria Veillonellaceae decreased. Linear discriminant analysis (LDA) revealed that SKS treatment increased the proportion of Streptococcus and decreased the proportions of Planctomycetes, Spirochaetes, Rhodocyclales, Actinomycetaceae, Veillonellaceae, and Dechloromonas. These changes were not observed in the control group. Correlation analysis revealed a negative association between Bifidobacterium , Blautia , Enterococcaceae_ Enterococcus , and clinical kidney function indicators, whereas Parabacteroides , Acinetobacter , Sutterella , Oscillospira , and Alistipes were positively correlated with kidney function.
Conclusion
SKS could delay the progression of kidney function in CKD stage 3–4 patients, possibly by modulating the dysbiosis of the gut microbiota. The close associations between certain gut microbiota and clinical kidney function indicators suggest that the gut microbiota could serve as a new therapeutic target for CKD. Clinical Trial Registration https://www.chictr.org.cn/ , Chinese Clinical Trial Registry Identifier: ChiCTR2200058493.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Nephrology, Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
- Clinical Research Center for Kidney Disease Xuzhou Medical University, Xuzhou, China.
- Department of Internal Medicine and Diagnostics, Xuzhou Medical University, Xuzhou, China.
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Jiangsu Province
Zitieren
APA
Zhang, W., Zhang, X., Xu, S., Waheed, Y. A., Xu, Y., Li, S., & Sun, D. (2025). The effects of Shenkang suppository on kidney function and gut microbiota in nondialysis patients with chronic kidney disease stages 3–4: A randomized controlled trial. Frontiers in Pharmacology, 16. https://doi.org/10.3389/fphar.2025.1621208
Vancouver
Zhang W, Zhang X, Xu S, Waheed YA, Xu Y, Li S, et al. The effects of Shenkang suppository on kidney function and gut microbiota in nondialysis patients with chronic kidney disease stages 3–4: A randomized controlled trial. Frontiers in Pharmacology. 2025;16. doi:10.3389/fphar.2025.1621208
BibTeX
@article{Zhang2025,
author = {Zhang, Weiwei and Zhang, Xin and Xu, Shuang and Waheed, Yousuf Abdulkarim and Xu, Yizhou and Li, Shulin and Sun, Dong},
title = {The effects of Shenkang suppository on kidney function and gut microbiota in nondialysis patients with chronic kidney disease stages 3–4: A randomized controlled trial},
journal = {Frontiers in Pharmacology},
year = {2025},
volume = {16},
doi = {10.3389/fphar.2025.1621208}
}
EUVIMED